Literature DB >> 30712258

Complex dietary polysaccharide modulates gut immune function and microbiota, and promotes protection from autoimmune diabetes.

Radhika Gudi1, Nicolas Perez2, Benjamin M Johnson1, M Hanief Sofi1, Robert Brown1, Songhua Quan2, Subha Karumuthil-Melethil2, Chenthamarakshan Vasu1.   

Abstract

The dietary supplement and prebiotic values of β-glucan-rich products have been widely recognized and dietary approaches for modulating autoimmunity have been increasingly explored, we assess the impact of oral administration of high-purity yeast β-glucan (YBG) on gut immune function, microbiota and type 1 diabetes (T1D) using mouse models. Oral administration of this non-digestible complex polysaccharide caused a dectin-1-dependent immune response involving increased expression of interleukin-10 (IL-10), retinaldehyde dehydrogenase (Raldh) and pro-inflammatory cytokines in the gut mucosa. YBG-exposed intestinal dendritic cells induced/expanded primarily Foxp3+ , IL-10+ and IL-17+ T cells, ex vivo. Importantly, prolonged oral administration of low-dose YBG at pre-diabetic stage suppressed insulitis and significantly delayed the appearance of T1D in non-obese diabetic (NOD) mice. Further, prolonged treatment with YBG showed increased Foxp3+ T-cell frequencies, and a significant change in the gut microbiota, particularly an increase in the abundance of Bacteroidetes and a decrease in the Firmicute members. Oral administration of YBG, together with Raldh-substrate and β-cell antigen, resulted in better protection of NOD mice from T1D. These observations suggest that YBG not only has a prebiotic property, but also an oral tolerogenic-adjuvant-like effect, and these features could be exploited for modulating autoimmunity in T1D.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  autoimmunity; gut microbiota; immune modulation; immune regulation; type 1 diabetes; yeast β-glucan

Mesh:

Substances:

Year:  2019        PMID: 30712258      PMCID: PMC6459770          DOI: 10.1111/imm.13048

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  59 in total

1.  Immunomodulation by orally administered beta-glucan in mice.

Authors:  I Suzuki; K Hashimoto; N Ohno; H Tanaka; T Yadomae
Journal:  Int J Immunopharmacol       Date:  1989

2.  Gut microbial metabolites limit the frequency of autoimmune T cells and protect against type 1 diabetes.

Authors:  Eliana Mariño; James L Richards; Keiran H McLeod; Dragana Stanley; Yu Anne Yap; Jacinta Knight; Craig McKenzie; Jan Kranich; Ana Carolina Oliveira; Fernando J Rossello; Balasubramanian Krishnamurthy; Christian M Nefzger; Laurence Macia; Alison Thorburn; Alan G Baxter; Grant Morahan; Lee H Wong; Jose M Polo; Robert J Moore; Trevor J Lockett; Julie M Clarke; David L Topping; Leonard C Harrison; Charles R Mackay
Journal:  Nat Immunol       Date:  2017-03-27       Impact factor: 25.606

3.  Fungal β-glucan, a Dectin-1 ligand, promotes protection from type 1 diabetes by inducing regulatory innate immune response.

Authors:  Subha Karumuthil-Melethil; Radhika Gudi; Benjamin M Johnson; Nicolas Perez; Chenthamarakshan Vasu
Journal:  J Immunol       Date:  2014-08-20       Impact factor: 5.422

4.  Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial.

Authors:  Ezio Bonifacio; Anette-G Ziegler; Georgeanna Klingensmith; Edith Schober; Polly J Bingley; Marietta Rottenkolber; Anke Theil; Anne Eugster; Ramona Puff; Claudia Peplow; Florian Buettner; Karin Lange; Jörg Hasford; Peter Achenbach
Journal:  JAMA       Date:  2015-04-21       Impact factor: 56.272

Review 5.  The Critical Roles of Polysaccharides in Gut Microbial Ecology and Physiology.

Authors:  Nathan T Porter; Eric C Martens
Journal:  Annu Rev Microbiol       Date:  2017-06-28       Impact factor: 15.500

6.  Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models.

Authors:  Feng Hong; Jun Yan; Jarek T Baran; Daniel J Allendorf; Richard D Hansen; Gary R Ostroff; Pei Xiang Xing; Nai-Kong V Cheung; Gordon D Ross
Journal:  J Immunol       Date:  2004-07-15       Impact factor: 5.422

Review 7.  C-type lectin-like receptors of the dectin-1 cluster: ligands and signaling pathways.

Authors:  Anthony Plato; Janet A Willment; Gordon D Brown
Journal:  Int Rev Immunol       Date:  2013-04       Impact factor: 5.311

8.  All-trans retinoic acid inhibits type 1 diabetes by T regulatory (Treg)-dependent suppression of interferon-gamma-producing T-cells without affecting Th17 cells.

Authors:  Yang-Hau Van; Wen-Hui Lee; Serina Ortiz; Mi-Heon Lee; Han-Jun Qin; Chih-Pin Liu
Journal:  Diabetes       Date:  2008-11-04       Impact factor: 9.461

9.  Baker's yeast beta glucan supplementation increases salivary IgA and decreases cold/flu symptomatic days after intense exercise.

Authors:  Brian K McFarlin; Katie C Carpenter; Tiffany Davidson; Meredith A McFarlin
Journal:  J Diet Suppl       Date:  2013-08-09

10.  Maternal treatment with short-chain fatty acids modulates the intestinal microbiota and immunity and ameliorates type 1 diabetes in the offspring.

Authors:  James C Needell; Diana Ir; Charles E Robertson; Miranda E Kroehl; Daniel N Frank; Danny Zipris
Journal:  PLoS One       Date:  2017-09-08       Impact factor: 3.240

View more
  12 in total

1.  Pretreatment with Yeast-Derived Complex Dietary Polysaccharides Suppresses Gut Inflammation, Alters the Microbiota Composition, and Increases Immune Regulatory Short-Chain Fatty Acid Production in C57BL/6 Mice.

Authors:  Radhika Gudi; Jada Suber; Robert Brown; Benjamin M Johnson; Chenthamarakshan Vasu
Journal:  J Nutr       Date:  2020-05-01       Impact factor: 4.798

Review 2.  The crucial role of early-life gut microbiota in the development of type 1 diabetes.

Authors:  He Zhou; Lin Sun; Siwen Zhang; Xue Zhao; Xiaokun Gang; Guixia Wang
Journal:  Acta Diabetol       Date:  2020-07-25       Impact factor: 4.280

3.  Gut microbiota differently contributes to intestinal immune phenotype and systemic autoimmune progression in female and male lupus-prone mice.

Authors:  Benjamin M Johnson; Marie-Claude Gaudreau; Radhika Gudi; Robert Brown; Gary Gilkeson; Chenthamarakshan Vasu
Journal:  J Autoimmun       Date:  2020-02-02       Impact factor: 7.094

4.  Immunological partners: the gut microbiome in homeostasis and disease.

Authors:  Anne Camille La Flamme; Simon Milling
Journal:  Immunology       Date:  2020-09       Impact factor: 7.397

5.  Dietary Additives and Supplements Revisited: The Fewer, the Safer for Liver and Gut Health.

Authors:  Rachel Golonka; Beng San Yeoh; Matam Vijay-Kumar
Journal:  Curr Pharmacol Rep       Date:  2019-06-10

Review 6.  Characterization and Analysis of Food-Sourced Carbohydrates.

Authors:  Leonie J Kiely; Rita M Hickey
Journal:  Methods Mol Biol       Date:  2022

7.  Activation of T cell checkpoint pathways during β-cell antigen presentation by engineered dendritic cells promotes protection from type 1 diabetes.

Authors:  Radhika R Gudi; Nicolas Perez; Subha Karumuthil-Melethil; Gongbo Li; Chenthamarakshan Vasu
Journal:  Immunology       Date:  2022-04-22       Impact factor: 7.215

Review 8.  Leveraging diet to engineer the gut microbiome.

Authors:  Mathis Wolter; Erica T Grant; Marie Boudaud; Alex Steimle; Gabriel V Pereira; Eric C Martens; Mahesh S Desai
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-09-27       Impact factor: 46.802

9.  Dynamics of Structural and Functional Changes in Gut Microbiota during Treatment with a Microalgal β-Glucan, Paramylon and the Impact on Gut Inflammation.

Authors:  Harrison B Taylor; Radhika Gudi; Robert Brown; Chenthamarakshan Vasu
Journal:  Nutrients       Date:  2020-07-23       Impact factor: 5.717

10.  Abundance and nuclear antigen reactivity of intestinal and fecal Immunoglobulin A in lupus-prone mice at younger ages correlate with the onset of eventual systemic autoimmunity.

Authors:  Wei Sun; Radhika R Gudi; Benjamin M Johnson; Chenthamarakshan Vasu
Journal:  Sci Rep       Date:  2020-08-31       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.